Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 18 December 2017, 13:40 HKT/SGT

Source: Eisai
Eisai Launches Educational Materials for Understanding Dementia
And Thinking About What One Can Do for Elementary and Secondary School Students in Japan

TOKYO, Dec 18, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today.

Five types of materials have been created, an educational DVD, textbooks for elementary and secondary school students as well as guides for instructors for each textbook. The DVD is a live action drama that tells the story of a family whose grandmother has dementia, and the contents enable viewers to learn what is dementia, the feelings of someone with dementia, and how to interact with people with dementia. In addition to an outline of the DVD, the textbooks contain basic knowledge on the aging society and dementia, as well as points on how to interact with people with dementia. The textbooks can be used in lessons or group work. The contents of the guides for instructors include model lesson plans, question and answer ideas and reference materials, as well as worksheets that can be used in group work.

Yukimichi Imai MD., PhD., president of the Japanese Society for Dementia Care, Director of Wako Hospital and supervisor for these materials, stated: "he person that begins suffering dementia is the one who is most distressed, and changes in symptoms may occur depending on how their family and friends act. In addition, the number of people with dementia in 2025 is estimated to reach approximately 7 million, affecting one out of every five elderly people aged over 65. However, with the rise of the nuclear family, there are more and more children and students who have few opportunities to interact with people with dementia. We believe that learning about dementia at school and thinking together about the feelings of those with dementia and how to interact with them will be a very important first step in this era of a progressively aging society. I highly endorse Eisai' efforts in creating these educational materials to think about living together with dementia."

Hideki Hayashi, representative corporate officer, Japan Business and CIO, Eisai, commented: "During our work on building communities that co-exist with dementia in collaboration with local governments, medical and nursing care professionals as well as other stakeholders, we recognized the need for dementia education in the classroom, and created educational materials that can be used in lessons such as group work to think about the feelings of people with dementia and how to interact with them, as well as for gaining knowledge on dementia. Through these materials, we hope that children will become concerned about their own grandparents and the state of elderly people in public spaces as a member of the local community, and that this will spark responses such as consulting surrounding adults when they sense something is amiss."

About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.

Dec 18, 2017 13:40 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Mar 8, 2018 13:33 HKT/SGT
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Mar 8, 2018 12:00 HKT/SGT
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Feb 27, 2018 09:33 HKT/SGT
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Feb 21, 2018 08:25 HKT/SGT
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Feb 16, 2018 07:34 HKT/SGT
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Feb 12, 2018 09:03 HKT/SGT
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Feb 1, 2018 16:20 HKT/SGT
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Jan 22, 2018 09:51 HKT/SGT
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Jan 20, 2018 18:32 HKT/SGT
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: